In the South African context, which factor should prompt consideration of a non-TNFα biologic?
Understand the Problem
The question asks which factor, in the context of South Africa, should lead a doctor to consider a non-TNFα biologic drug. TNFα biologics are a class of drugs used to treat inflammatory conditions. The question implies there's a specific reason related to South Africa that would make another type of biologic preferable.
Answer
A higher incidence of tuberculosis (TB) in patients receiving TNF-α biologic therapies may prompt consideration of a non-TNFα biologic.
In the South African context, a higher incidence of tuberculosis (TB) disease in patients receiving TNF-α biologic therapies compared to non-TNF-α biologic therapies may prompt consideration of a non-TNFα biologic.
Answer for screen readers
In the South African context, a higher incidence of tuberculosis (TB) disease in patients receiving TNF-α biologic therapies compared to non-TNF-α biologic therapies may prompt consideration of a non-TNFα biologic.
More Information
The increased risk of TB is a significant concern when considering biologic therapies in South Africa, where TB prevalence is high.
Tips
It is important to consider local guidelines and recommendations when making treatment decisions, as these may vary depending on the specific context and local disease patterns.
Sources
- Incident tuberculosis disease in patients receiving biologic therapies ... - pmc.ncbi.nlm.nih.gov
AI-generated content may contain errors. Please verify critical information
